NCT00909584View on ClinicalTrials.gov

Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Severe Chronic Neutropenia
Interventions
DRUG

Ezatiostat Hydrochloride

Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)

Trial Locations (4)

20817

Center for Cancer and Blood Disorders, Bethesda

78229

Cancer Care Centers of South Texas, San Antonio

98195

University of Washington Medical Center, Seattle

48109-0238

University of Michigan Hospital, Ann Arbor

Sponsors

Lead Sponsor

Telik
All Listed Sponsors
lead

Telik

INDUSTRY